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Introduction: In IPASS (IRESSA Pan-Asia Study), clinically se-
lected patients with pulmonary adenocarcinoma received first-line
gefitinib or carboplatin/paclitaxel. This preplanned, exploratory
analysis was conducted to increase understanding of the use of
surrogate samples, such as serum, versus tumor biopsy samples for
determining EGFR mutation status in the Japanese cohort (n 233).
Methods: EGFR mutations were assessed using tumor tissue-de-
rived DNA (n  91) and circulating free (cf) DNA from pretreat-
ment serum samples (n  194).
Results: Fewer patients were EGFR mutation positive when as-
sessed using pretreatment cfDNA (23.7%) versus tumor tissue-
derived DNA (61.5%). cfDNA results identified no false positives
but a high rate of false negatives (56.9%). There was a significant
interaction between cfDNA EGFR mutation status and treatment for
progression-free survival (PFS) (p  0.045). PFS was significantly
longer and objective response rate (ORR) higher with gefitinib than
carboplatin/paclitaxel in the cfDNA EGFR mutation-positive sub-
group (PFS: hazard ratio [HR], 0.29; 95% confidence interval [CI],
0.14–0.60; p  0.001; ORR: odds ratio [OR], 1.71; 95% CI,
0.48–6.09; 75.0% versus 63.6%; p  0.40). There was a slight
numerical advantage in PFS and ORR for gefitinib over carboplatin/
paclitaxel in the cfDNA EGFR mutation-negative subgroup, likely
due to the high rate of false negatives within this subgroup.
Conclusions: These results merit further investigation to determine
whether alternative sources of tumor DNA, such as cfDNA in
serum, could be used for determining EGFR mutation status in
future; currently, where a sample is available, analysis of tumor
material is recommended.
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The epidermal growth factor receptor (EGFR) superfamilyhas been implicated in the regulation of tumor cell biol-
ogy and, as such, has emerged as a therapeutic target.1 In
2004, mutations in the EGFR were reported to be associated
with sensitivity to EGFR tyrosine kinase inhibitors (EGFR-
TKIs).2–4 The presence of such mutations in tumor tissue is
associated with a number of clinical factors including Asian
origin, female sex, adenocarcinoma histology, and a never-
smoking history, and these factors have additionally been
correlated with response to gefitinib (IRESSA, AstraZeneca,
Macclesfield, UK), an EGFR-TKI.5
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The IRESSA Pan-Asia Study (IPASS) compared ge-
fitinib with carboplatin/paclitaxel as first-line treatment in
1217 never-smokers/light ex-smokers with advanced adeno-
carcinoma of the lung in East Asia.6 Subgroup analysis of
patients with EGFR mutations (n  261) detected in DNA
derived from tumor tissue samples demonstrated significantly
longer progression-free survival (PFS) with gefitinib versus
carboplatin/paclitaxel (hazard ratio [HR], 0.48; 95% confi-
dence interval [CI], 0.36–0.64; p  0.001).6 In the EGFR
mutation-negative (M) subgroup (n  176), PFS was sig-
nificantly longer with carboplatin/paclitaxel versus gefitinib
(HR, 2.85; 95% CI, 2.05–3.98; p  0.001). Objective re-
sponse rates (ORR) were 71.2% versus 47.3% (p  0.001)
and 1.1% versus 23.5% (p  0.001) with gefitinib versus
carboplatin/paclitaxel in EGFR M and M patients,
respectively.
The difficulties of collecting sufficient tumor tissue for
biomarker analyses have stimulated interest in analyses using
surrogate samples, such as serum and plasma samples, which
frequently contain circulating free (cf) DNA derived from
tumor tissues. Previous studies in relatively few patients had
detected EGFR mutations in cfDNA in serum or plasma
samples and suggested that using such methodology to pre-
dict response to gefitinib was worthy of further evalua-
tion.7–12 However, most of these studies were retrospective.
Herein, we report the evaluation of EGFR mutations in
cfDNA from serum samples of patients in the IPASS study
recruited in Japan. This preplanned, exploratory analysis was
conducted to increase the understanding of the use of surro-
gate samples, such as serum, versus tumor biopsy samples for
determining EGFR mutation status.
MATERIALS AND METHODS
Study Design and Patients
Full details of the IPASS study design (ClinicalTrials.
gov identifier NCT00322452) have been published previ-
ously.6 Planned objectives of this substudy of IPASS were
evaluations of efficacy between the gefitinib and carboplatin/
paclitaxel treatment groups by cfDNA EGFR mutation status
from pretreatment serum samples and evaluation of the
concordance between EGFR mutation status in pretreat-
ment cfDNA versus tumor. Comparison of EGFR mutation
status in pretreatment versus postprogression serum sam-
ples was also performed; however, not all patients with a
pretreatment sample had a postprogression sample, which
limited the comparison. In addition, comparisons with post-
progression serum and pretreatment pleural effusion samples
are reported in Supplemental Digital Content 1 (Methods
http://links.lww.com/JTO/A152). Preplanned analysis of the
Japanese subset of the IPASS population was performed to
meet Japanese regulatory requirements.
All patients provided written informed consent. Provi-
sion of samples for biomarker research was optional and
involved separate consent procedures for tumor and serum
sampling. An independent ethics committee at each partici-
pating institution approved the study protocol. The study was
conducted in accordance with the Declaration of Helsinki, the
International Conference on Harmonisation Guidelines for
Good Clinical Practice, applicable regulatory requirements,
and AstraZeneca’s policy on bioethics.
Biomarker Analyses
Sample collection and DNA extraction are described in
Supplemental Digital Content 1 (Methods http://links.lww.
com/JTO/A152). EGFR mutations were detected using the
DxS EGFR Mutation Test Kit for Research Use Only (DxS,
Manchester, UK), which combines Amplification Refractory
Mutation System (ARMS) (allele-specific polymerase chain
reaction [PCR]) with the Scorpions real-time PCR technol-
ogy.13,14 Modified run conditions and cutoffs (delta Ct values
[dCt]) used to define M samples for cfDNA derived from
serum and pleural effusion samples were as follows: 50
cycles of PCR were carried out and the dCt for exon 19
deletions was 12, L858R was 14, and T790M was 8 (for
tumor DNA, 40 cycles of PCR were carried out and the dCt
cutoffs were 9, 11, and 8, respectively). In analyses of tumor
DNA, all 29 mutations detected by the kit were assayed (19
deletions in exon 19, L858R, T790M, L861Q, G719X [S, A,
or C], S768I, and 3 insertions in exon 20); whereas for serum
and pleural effusion samples, the 21 most common mutations
(19 deletions in exon 19, L858R, and T790M) were assayed
(to make the best use of limited cfDNA yield). Samples were
tested in duplicate, and only if both replicates were positive
for at least one of the mutations was the sample defined as
M. Patients without a tumor sample evaluable for mutation
analysis and samples which were not successfully analyzed
were classified as EGFR mutation unknown. Biomarker sam-
ples were assayed blinded to clinical outcome and random-
ized treatment.
Statistical Analyses
Serum samples were collected for patients recruited in
Japan and who consented to this optional analysis. Analyses
of efficacy end points comparing treatment groups in the
Japanese subset (intent-to-treat [ITT] population) were as-
sessed as described previously for the overall IPASS popu-
lation.6 However, for the analyses in the cfDNA M and
M subgroups, the prespecified covariates of World Health
Organization (WHO) performance status (PS), smoking his-
tory, and sex could not be included as covariates because of
the small number of patients who had a WHO PS 2, were
ex-smokers, or were males; therefore, models without cova-
riates were used. Because of the lack of power to detect
treatment differences, the result of the Japanese subset should
be interpreted with caution, taking into account the associated
variability and overlap in plausible range of effects (CIs).
Analyses comparing treatment groups were performed for
PFS (by Cox proportional hazards model) and ORR (by
logistic regression model) in subgroups defined by cfDNA
EGFR mutation status. A test for interaction between cfDNA
EGFR mutation status (M or M) and treatment was used
to assess whether the PFS treatment effect was statistically
different between subgroups.
Comparison of pretreatment cfDNA versus tumor
EGFR mutations was based on the 21 mutations analyzed for
cfDNA using patients with known mutation status (M or
M) in both samples. The sensitivity, specificity, positive
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and negative predictive values and their exact 95% CIs, and
the kappa coefficient and 95% CI, for EGFR mutation status
in serum samples, were evaluated assuming that the EGFR
mutation status in tumor tissue was a true reflection of tumor
biology. The proportion of concordance between cfDNA and
tumor was calculated on a similar basis by excluding patients
judged as unknown using either cfDNA or tumor samples.
RESULTS
Patients
In total, 233 patients from Japan were randomized to
study treatment (19.1% of the overall IPASS population).
Preplanned evaluations of efficacy, quality of life, and safety
for the overall Japanese study population have been previ-
ously presented15,16 and are summarized in Supplemental
Digital Content 2 (Results http://links.lww.com/JTO/A153)
and 3 (Figure http://links.lww.com/JTO/A154). The patient
disposition for the Japanese subset of IPASS is shown in
Figure 1.
EGFR Mutation Status
An evaluable DNA sample for EGFR mutation status
derived from tumor tissue was available for 91 patients; of
these, 56 (61.5%) patients were EGFR M, with a lower
proportion of EGFR M patients in the gefitinib group
compared with the carboplatin/paclitaxel group (52.3%
[23/44] versus 70.2% [33/47]) (Figure 2). A total of 194
patients provided a pretreatment serum sample for muta-
tion analysis; all were evaluable. Of these, 46 (23.7%)
patients were cfDNA EGFR M (25.5% [24/94] and
22.0% [22/100] in the gefitinib and carboplatin/paclitaxel
groups, respectively) (Figure 2). Data from pretreatment
pleural effusion (9 patients) and postprogression serum
analyses (144 patients) are presented in Supplemental
Digital Content 2 (Results http://links.lww.com/JTO/A153)
and 4 (Table http://links.lww.com/JTO/A155).
Demographic and Baseline Characteristics of
Patients with Known EGFR Mutation Status
Key demographic and baseline characteristics for pa-
tients with known (i.e., evaluable) cfDNA or tumor EGFR
mutation status were generally consistent with the overall
Japanese study population (Table 1).
Pretreatment cfDNA EGFR Mutation Status and
Clinical Outcomes
The subset of patients with known cfDNA EGFR mu-
tation status could be assumed to be representative of the
overall Japanese study population (and therefore the overall
study population) as shown by similar PFS and ORR results
(Table 1).
A significant interaction between cfDNA EGFR muta-
tion status and treatment was evident for PFS (interaction test
p  0.045). PFS was significantly longer with gefitinib than
carboplatin/paclitaxel in the cfDNA EGFR M subgroup
(HR, 0.29; 95% CI, 0.14–0.60; p  0.001) (Figure 3A). In
the cfDNA EGFR M subgroup, there were no significant
differences for PFS with gefitinib compared with carboplatin/
paclitaxel (HR, 0.88; 95% CI, 0.61–1.28; p  0.50) (Figure
3B). However, the HR was not constant over time. We
EGFR EGFR
FIGURE 1. CONSORT diagram
representing patient disposition
(including number of patients with
tumor tissue or serum evaluable for
EGFR mutation status). EGFR, epi-
dermal growth factor receptor.
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believe that this result was due to the high rate of false
negative results as described later (i.e., this group included
both tumor EGFR M and M patients).
In the cfDNA M subgroup, ORR was not signifi-
cantly different in the gefitinib group compared with carbo-
platin/paclitaxel treatment (75.0% [18/24] and 63.6% [14/
22], respectively; odds ratio [OR], 1.71; 95% CI, 0.48–6.09;
p  0.40). In the cfDNA M subgroup, there were no
significant differences in ORR with gefitinib compared with
carboplatin/paclitaxel (27.1% [19/70] and 21.8% [17/78],
respectively; OR, 1.34; 95% CI, 0.63–2.84; p 0.45) (Figure
4). Again, this subgroup included both tumor EGFR M and
M patients as described later.
The results for clinical outcome by EGFR mutation status
(M, M) for the Japanese subset of patients with known
tumorEGFRmutation status (n 91) are included in Supplemental
Digital Content 2 (Results http://links.lww.com/JTO/A153).
Comparison of EGFR Mutation Status in
Pretreatment cfDNA and Tumor Tissue
A total of 108 patients had a known mutation result by
cfDNA but not by tumor; 5 patients had a known mutation
FIGURE 2. Flow and results of EGFR mutation
analysis. aSample positive for 1 of 21 mutations
tested; detected 19 deletions in exon 19, L858R,
and T790M. bSample positive for 1 of 29 muta-
tions tested; detected 19 deletions in exon 19,
L858R, T790M, L861Q, G719S, G719A, G719C,
S768l; 3 insertions in exon 20. cSample negative
for all 21 mutations tested. dSample negative for
all 29 mutations tested. eUnknown EGFR muta-
tions: no sample available or failed analysis. f86
patients had known mutation status by both tumor
tissue and cfDNA. C/P, carboplatin/paclitaxel; EGFR,
epidermal growth factor receptor; M, mutation;
M, mutation-positive; M, mutation-negative.
TABLE 1. Patient Demographics, Baseline Characteristics, and Efficacy (PFS and ORR) for
Patients with Samples (cfDNA or Tumor) Evaluable for EGFR Mutation Status Compared
with the Overall Japanesea Study Population (Japanese ITT Population)
Evaluable for EGFR
Mutation Status
(cfDNA) (n  194)b
Evaluable for EGFR
Mutation Status





Female 172 (88.7) 84 (92.3) 204 (87.6)
WHO PS 0/1 185 (95.4) 89 (97.8) 223 (95.7)
Never-smoker 177 (91.2) 83 (91.2) 212 (91.0)
Stage IIIB 66 (34.0) 27 (29.7) 73 (31.3)
Age 65 yr 97 (50.0) 45 (49.5) 121 (51.9)
Efficacy
PFS HRc (95% CI) 0.68 (0.49–0.95) 1.08 (0.68–1.72) 0.69 (0.51–0.94)
ORR ORd (95% CI) 1.45 (0.80–2.61) 0.99 (0.41–2.40)e 1.34 (0.78–2.30)
a Refers to the country of recruitment and not necessarily to racial origin.
b Includes both mutation-positive and mutation-negative samples.
c HR 1 indicates a difference in favor of gefitinib.
d OR 1 indicates a greater chance of response on gefitinib.
e These results should be interpreted with caution as the logistic regression model did not converge.
cfDNA, circulating free DNA; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; ITT,
intent-to-treat; OR, odds ratio; ORR, objective response rate; PFS, progression-free survival; PS, performance status; WHO, World
Health Organization.
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result by tumor but not cfDNA (no serum sample provided);
and 86 patients had a known mutation status by both tumor
and cfDNA.
Of the 86 patients who had a known tumor and cfDNA
mutation status, no false positives were identified (i.e., no
samples were tumor M but cfDNA M). All 22 patients
identified as cfDNA EGFR M were tumor EGFR M, i.e.,
the positive predictive value was 100% (all samples that were
cfDNA M were tumor M) and the specificity was 100%
(all samples that were tumor M were cfDNA M) (Table
2). However, the rate of false negatives was high: 29/51
(56.9%) of patients identified as tumor EGFR M were
cfDNA EGFR M (Table 2).
EGFR Mutation Types in Pretreatment cfDNA
and Tumor Tissue
Of the patients classified as EGFR M at pretreatment
by both tumor and cfDNA, all had the same mutation type in
FIGURE 3. Kaplan-Meier curves of progression-free survival in cfDNA EGFR mutation-positive (A) and cfDNA EGFR mutation-
negative (B) patients in the Japanese subset of IPASS. HR 1 indicates a difference in favor of gefitinib. CI, confidence interval;
cfDNA, circulating free DNA; EGFR, epidermal growth factor receptor; HR, hazard ratio.
p
p
FIGURE 4. Objective response rates by treatment and by
cfDNA (serum) EGFR mutation status (Japanese ITT popula-
tiona). aRefers to the country of recruitment and not neces-
sarily to racial origin. bThere was a high rate of false-negative
results, i.e., this group included both tumor EGFR M and
M patients. OR 1 implies a greater chance of response
on gefitinib. OR, CI, and p values from logistic regression.
cfDNA, circulating free DNA; CI, confidence interval; EGFR,
epidermal growth factor receptor; ITT, intent-to-treat; M,
mutation-positive; M, mutation-negative; OR, odds ratio.
TABLE 2. Comparison of EGFR Mutation Status in cfDNA
and Tumor Samples in 86 Patients with a Known EGFR
Mutation Status Using Both Methods (Japanesea ITT
Population)
Mutation Status (Tumor Tissue), n
M M Total
Mutation status (cfDNA), n
M 22 0 22
M 29 35 64
Total 51 35 86
Sensitivity  43.1% (22 cfDNA M out of 51 tumor M).b
Specificity  100% (all 35 tumor M- were cfDNA M).b
Positive predictive value  100% (all 22 cfDNA M were tumor M).b
Negative predictive value  54.7% (35 tumor M- out of 64 cfDNA M).b
Concordance  66.3% (cfDNA and tumor results agreed in 57 of 86 cases).b,c
a Refers to the country of recruitment and not necessarily to racial origin.
b Those with a known EGFR mutation status using both methods.
c Kappa coefficient 0.38 (95% CI, 0.24–0.53).
cfDNA, circulating free DNA; CI, confidence interval; EGFR, epidermal growth
factor receptor; ITT, intent-to-treat; M, mutation positive; M, mutation negative.
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tumor and cfDNA except one patient who had exon 20
T790M and exon 21 L858R by tumor but exon 20 T790M
only by cfDNA (Table 3).
DISCUSSION
The feasibility of using cfDNA to detect EGFR muta-
tions was assessed in the Japanese subset of patients from the
IPASS study. The proportion of patients identified as EGFR
M was lower when assessed in cfDNA (23.7%) compared
with tumor tissue (61.5%). Although cfDNA results identified
no false positives, a high rate of false negatives (56.9%) was
observed, with more than half of the tumor M patients not
detected by cfDNA testing (of patients with evaluable muta-
tion status from both cfDNA and tumor). Further research
into appropriate methods and analysis needs to be performed
before it could be accepted as an option in the diagnostic or
screening setting. If larger patient series confirmed the ab-
sence of false-positive results and demonstrated an improve-
ment or lowering of false-negative results, serum testing may
prove useful for patients for whom tumor samples are not
available.
Testing of biopsied tumor tissue remains the current
recommended method for EGFR mutation analysis.8 How-
ever, tumor tissue is often difficult to obtain, particularly from
patients with advanced non-small cell lung cancer (NSCLC),
and a lack of tumor cells in a given sample and subsequently
failure on pathological examination can make EGFR muta-
tion analysis very difficult. The increased recognition of the
relevance of mutation testing to treatment selection may
stimulate efforts to better obtain tissue for EGFR mutation
testing in the future. In the meantime, detection of EGFR
mutation status in cfDNA derived from serum/plasma may
allow patients without diagnostic tumor material the oppor-
tunity to benefit from personalized treatment and also has a
use in the clinical trial setting where tumor material is not
always available.
Although minimally invasive, the use of serum as a
nontumor surrogate sample may be limited by the amount of
cfDNA available in the sample, meaning that some positive
samples are not detected. In addition, some patients may not
have cf tumor DNA as their tumors may not be releasing this
material into the bloodstream, giving rise to false-negative
results. Because of the limited yields of cfDNA obtained
from serum, two changes (in addition to duplicate tests) were
made to the EGFR mutation ARMS kit used to detect EGFR
mutations in this study: an increase in the number of PCR
cycles and an alteration of the cutoffs used to define M
samples (dCt values). Further analysis is underway to investigate
whether these conditions are the most appropriate and whether
less stringent settings could result in more true positives (fewer
false negatives) while retaining no false positives.
There have been several reports on the detection of
cfDNA EGFR mutation status using different methods. A
significant correlation between cfDNA EGFR mutation status
and clinical response to gefitinib was found in two previous
small studies that assessed cfDNA EGFR mutation status
using the ARMS method of detection, a highly sensitive (1%
sensitive) targeted technique to detect specific known EGFR
mutations.9,11 Other screening techniques detect all EGFR
mutations, known and novel variants, by PCR amplification
followed by sequencing, pyrosequencing, or melt analysis
(10–30% sensitivity).8 However, although these methods are
widely used for EGFR mutation analysis of DNA derived
from tumor tissue, not all of these methods have demon-
strated utility for EGFR mutation analysis of cfDNA. In a
small study that used DNA sequencing to detect EGFR
mutations in serum, mutations were more frequently ob-
served in patients experiencing partial response or stable
disease compared with those whose disease progressed, al-
though the difference did not reach statistical significance.10
No statistically significant association between cfDNA EGFR
mutation status and PFS by multivariate analysis (HR, 1.48;
95% CI, 0.93–2.36; p  0.09) was found in the study by
Rosell et al.12 which assessed EGFR mutations by PCR-based
methods in the presence of a protein nucleic acid (PNA)
clamp in the cfDNA extracted from serum of 164 patients









Exon 20 T790M and
Exon 21 L858R Negative Unknown Total
Exon 19 deletions only 11 0 0 0 0 15 26
Exon 20 T790M only 0 0 0 1 0 1 2
Exon 21 L858R only 0 0 10 0 0 8 18
Exon 20 T790M and exon 21 0 0 0 0 0 0 0
L858R
Negative 18 0 11 0 35 84 148
Unknown 2 1 0 0 2 34 39
Total 31 1 21 1 37 142 233
The categories are mutually exclusive. The categories “Exon 19 deletions and exon 20 T790M” and “Exon 19 deletions and exon 21 L858R” were 0 for both tumor and cfDNA
and have been omitted from the table.
a Refers to the country of recruitment and not necessarily to racial origin.
b Mutations that were tested in tumor tissue samples but not serum included: exon 20 insertion, exon 21 L861Q, exon 18 G719X, and exon 20 S768I. Two patients with tumor
samples had these mutations (1 with exon 20 insertion and 1 with exon 21 L861Q). These patients were excluded from the comparative analysis of mutation detection by sample
type.
cfDNA, circulating free DNA; EGFR, epidermal growth factor receptor; ITT, intent-to-treat.
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treated with erlotinib. In another study that used denaturing
high-performance liquid chromatography to analyze for mu-
tations in exons 19 and 21 from matched plasma and tumor
samples, patients with plasma EGFR mutations had signifi-
cantly higher ORR and prolonged PFS.7 The present study
using ARMS demonstrated that the treatment effect for the
Japanese cfDNA EGFR M subgroup followed the same
pattern as the tumor EGFR M subgroup of the overall
IPASS population (i.e., PFS HR significantly in favor of
gefitinib and higher ORR with gefitinib versus carboplatin/
paclitaxel).6 There was a significant interaction between
cfDNA EGFR mutation status and treatment for PFS.
Any variance in concordance rates for mutation results
between pretreatment serum versus tumor tissue (66.3% in
our study and between 58 and 93% in previously reported
studies)7,9–11 may be attributed to different methods of ex-
traction, detection, run conditions, the size and yield of the
DNA fragments, and the fact that cfDNA may not be present
in the circulation of all patients with NSCLC. For example,
targeted sequences amplified by ARMS are short, at 100–150
bp, leading to decreased assay failure rates (particularly from
formalin-fixed paraffin-embedded material or fragments of
cfDNA) compared with sequencing methods, which tend to
involve the amplification of longer target sequences of 150–
250 bp or above.8,13,14,17,18
In patients who were cfDNA EGFR M in this study, no
significant difference for PFS was seen with gefitinib compared
with carboplatin/paclitaxel; however, the HR was not constant
over time (as was observed for the overall Japanese study
population). These results should be interpreted with caution as
there was a high rate of false negatives, and this subgroup is
likely to include tumor EGFR M and M patients.
In conclusion, these results merit further investigation
to determine whether alternative samples, including serum or
plasma, may be considered for determining EGFR mutation
status in future, particularly in cases where diagnostic tumor
material is not available. Currently, analysis of tumor mate-
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